Disc Medicine, Inc. announced its plans for 2025, highlighting key developments in its clinical programs focused on hematologic diseases. The company will discuss plans for NDA submission of ...
FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong ...
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine received a Complete Response Letter (CRL) from FDA for its New Drug Application (NDA) for bitopertin as a treatment for erythropoietic protoporphyria (EPP), delaying a potential ...
Disc Medicine (IRON) has made great progress in advancing its lead candidate for its pipeline known as bitopertin for the treatment of patients with erythropoietic protoporphyria [EPP] and X-linked ...
Disc Medicine has announced a US Food and Drug Administration (FDA) agreement on the regulatory path for its investigational drug bitopertin in treating the rare skin condition erythropoietic ...
Type 2 diabetes alters the behavior of discs in the vertebral column, making them stiffer, and also causes the discs to change shape earlier than normal. As a result, the disc's ability to withstand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results